1
|
Kazandjian D: Multiple myeloma
epidemiology and survival: A unique malignancy. Semin Oncol.
43:676–681. 2016.PubMed/NCBI View Article : Google Scholar
|
2
|
Morgan GJ, Walker BA and Davies FE: The
genetic architecture of multiple myeloma. Nat Rev Cancer.
12:335–348. 2012.PubMed/NCBI View
Article : Google Scholar
|
3
|
Mateos MV and Landgren O: MGUS and
smoldering multiple myeloma: Diagnosis and epidemiology. Cancer
Treat Res. 169:3–12. 2016.PubMed/NCBI View Article : Google Scholar
|
4
|
Glavey SV, Manier S, Sacco A, Salem K,
Kawano Y, Bouyssou J, Ghobrial IM and Roccaro AM: Epigenetics in
multiple myeloma. Cancer Treat Res. 169:35–49. 2016.PubMed/NCBI View Article : Google Scholar
|
5
|
Wilkins JF: Genomic imprinting and
methylation: Epigenetic canalization and conflict. Trends Genet.
21:356–365. 2005.PubMed/NCBI View Article : Google Scholar
|
6
|
Liyanage VR, Jarmasz JS, Murugeshan N, Del
Bigio MR, Rastegar M and Davie JR: DNA modifications: Function and
applications in normal and disease States. Biology (Basel).
3:670–723. 2014.PubMed/NCBI View Article : Google Scholar
|
7
|
Wong KY and Chim CS: DNA methylation of
tumor suppressor protein-coding and non-coding genes in multiple
myeloma. Epigenomics. 7:985–1001. 2015.PubMed/NCBI View Article : Google Scholar
|
8
|
Wilusz JE, Sunwoo H and Spector DL: Long
noncoding RNAs: Functional surprises from the RNA world. Genes Dev.
23:1494–1504. 2009.PubMed/NCBI View Article : Google Scholar
|
9
|
Schmitt AM and Chang HY: Long noncoding
RNAs in cancer pathways. Cancer Cell. 29:452–463. 2016.PubMed/NCBI View Article : Google Scholar
|
10
|
Wang W, Wang J, Chen M, Liang Y, LI Z,
Zhang Z and Jing H: 5-Azacitidine remolds the methylation status
and inhibits growth in multiple myeloma. Blood. 126(4817)2015.
|
11
|
Miyoshi N, Wagatsuma H, Wakana S,
Shiroishi T, Nomura M, Aisaka K, Kohda T, Surani MA, Kaneko-Ishino
T and Ishino F: Identification of an imprinted gene, Meg3/Gtl2 and
its human homologue MEG3, first mapped on mouse distal chromosome
12 and human chromosome 14q. Genes Cells. 5:211–220.
2000.PubMed/NCBI View Article : Google Scholar
|
12
|
Zhang X, Gejman R, Mahta A, Zhong Y, Rice
KA, Zhou Y, Cheunsuchon P, Louis DN and Klibanski A: Maternally
expressed gene 3, an imprinted noncoding RNA gene, is associated
with meningioma pathogenesis and progression. Cancer Res.
70:2350–2358. 2010.PubMed/NCBI View Article : Google Scholar
|
13
|
Sun L, Li Y and Yang B: Downregulated long
non-coding RNA MEG3 in breast cancer regulates proliferation,
migration and invasion by depending on p53's transcriptional
activity. Biochem Biophys Res Commun. 478:323–329. 2016.PubMed/NCBI View Article : Google Scholar
|
14
|
Ying L, Huang Y, Chen H, Wang Y, Xia L,
Chen Y, Liu Y and Qiu F: Downregulated MEG3 activates autophagy and
increases cell proliferation in bladder cancer. Mol Biosyst.
9:407–411. 2013.PubMed/NCBI View Article : Google Scholar
|
15
|
Zhuo H, Tang J, Lin Z, Jiang R, Zhang X,
Ji J, Wang P and Sun B: The aberrant expression of MEG3 regulated
by UHRF1 predicts the prognosis of hepatocellular carcinoma. Mol
Carcinog. 55:209–219. 2016.PubMed/NCBI View
Article : Google Scholar
|
16
|
Shen X, Bai H, Zhu H, Yan Q, Yang Y, Yu W,
Shi Q, Wang J, Li J and Chen L: Long non-coding RNA MEG3 functions
as a competing endogenous RNA to regulate HOXA11 expression by
sponging miR-181a in multiple myeloma. Cell Physiol Biochem.
49:87–100. 2018.PubMed/NCBI View Article : Google Scholar
|
17
|
Astuti D, Latif F, Wagner K, Gentle D,
Cooper WN, Catchpoole D, Grundy R, Ferguson-Smith AC and Maher ER:
Epigenetic alteration at the DLK1-GTL2 imprinted domain in human
neoplasia: Analysis of neuroblastoma, phaeochromocytoma and Wilms'
tumour. Br J Cancer. 92:1574–1580. 2005.PubMed/NCBI View Article : Google Scholar
|
18
|
Kagami M, O'Sullivan MJ, Green AJ, Watabe
Y, Arisaka O, Masawa N, Matsuoka K, Fukami M, Matsubara K, Kato F,
et al: The IG-DMR and the MEG3-DMR at human chromosome 14q32.2:
Hierarchical interaction and distinct functional properties as
imprinting control centers. PLoS Genet. 6(e1000992)2010.PubMed/NCBI View Article : Google Scholar
|
19
|
Li J, Bian EB, He XJ, Ma CC, Zong G, Wang
HL and Zhao B: Epigenetic repression of long non-coding RNA MEG3
mediated by DNMT1 represses the p53 pathway in gliomas. Int J
Oncol. 48:723–733. 2016.PubMed/NCBI View Article : Google Scholar
|
20
|
Sheng X and Li J, Yang L, Chen Z, Zhao Q,
Tan L, Zhou Y and Li J: Promoter hypermethylation influences the
suppressive role of maternally expressed 3, a long non-coding RNA,
in the development of epithelial ovarian cancer. Oncol Rep.
32:277–285. 2014.PubMed/NCBI View Article : Google Scholar
|
21
|
Benetatos L, Hatzimichael E, Dasoula A,
Dranitsaris G, Tsiara S, Syrrou M, Georgiou I and Bourantas KL: CpG
methylation analysis of the MEG3 and SNRPN imprinted genes in acute
myeloid leukemia and myelodysplastic syndromes. Leuk Res.
34:148–153. 2010.PubMed/NCBI View Article : Google Scholar
|
22
|
Li ZY, Yang L, Liu XJ, Wang XZ, Pan YX and
Luo JM: The long noncoding RNA MEG3 and its target miR-147 regulate
JAK/STAT pathway in advanced chronic myeloid leukemia.
EBioMedicine. 34:61–75. 2018.PubMed/NCBI View Article : Google Scholar
|
23
|
Greipp PR, San Miguel J, Durie BG, Crowley
JJ, Barlogie B, Bladé J, Boccadoro M, Child JA, Avet-Loiseau H,
Kyle RA, et al: International staging system for multiple myeloma.
J Clin Oncol. 23:3412–3420. 2005.PubMed/NCBI View Article : Google Scholar
|
24
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
25
|
Murphy SK, Wylie AA, Coveler KJ, Cotter
PD, Papenhausen PR, Sutton VR, Shaffer LG and Jirtle RL: Epigenetic
detection of human chromosome 14 uniparental disomy. Hum Mutat.
22:92–97. 2003.PubMed/NCBI View Article : Google Scholar
|
26
|
Benetatos L, Dasoula A, Hatzimichael E,
Georgiou I, Syrrou M and Bourantas KL: Promoter hypermethylation of
the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma. Clin
Lymphoma Myeloma. 8:171–175. 2008.PubMed/NCBI View Article : Google Scholar
|
27
|
Sigmon J and Larcom LL: The effect of
ethidium bromide on mobility of DNA fragments in agarose gel
electrophoresis. Electrophoresis. 17:1524–1527. 1996.PubMed/NCBI View Article : Google Scholar
|
28
|
Robertson KD: DNA methylation and human
disease. Nat Rev Genet. 6:597–610. 2005.PubMed/NCBI View
Article : Google Scholar
|
29
|
Schmidt M, Dehne S and Feierabend J:
Post-transcriptional mechanisms control catalase synthesis during
its light-induced turnover in rye leaves through the availability
of the hemin cofactor and reversible changes of the translation
efficiency of mRNA. Plant J. 31:601–613. 2002.PubMed/NCBI View Article : Google Scholar
|
30
|
Zhang X, Rice K, Wang Y, Chen W, Zhong Y,
Nakayama Y, Zhou Y and Klibanski A: Maternally expressed gene 3
(MEG3) noncoding ribonucleic acid: Isoform structure, expression,
and functions. Endocrinology. 151:939–947. 2010.PubMed/NCBI View Article : Google Scholar
|
31
|
Jin L, Cai Q, Wang S, Wang S, Mondal T,
Wang J and Quan Z: Long noncoding RNA MEG3 regulates LATS2 by
promoting the ubiquitination of EZH2 and inhibits proliferation and
invasion in gallbladder cancer. Cell Death Dis.
9(1017)2018.PubMed/NCBI View Article : Google Scholar
|
32
|
Chak WP, Lung RW, Tong JH, Chan SY, Lun
SW, Tsao SW, Lo KW and To KF: Downregulation of long non-coding RNA
MEG3 in nasopharyngeal carcinoma. Mol Carcinog. 56:1041–1054.
2017.PubMed/NCBI View Article : Google Scholar
|
33
|
Muller PA and Vousden KH: Mutant p53 in
cancer: New functions and therapeutic opportunities. Cancer Cell.
25:304–317. 2014.PubMed/NCBI View Article : Google Scholar
|
34
|
Chng WJ, Price-Troska T, Gonzalez-Paz N,
Van Wier S, Jacobus S, Blood E, Henderson K, Oken M, Van Ness B,
Greipp P, et al: Clinical significance of TP53 mutation in myeloma.
Leukemia. 21:582–584. 2007.PubMed/NCBI View Article : Google Scholar
|
35
|
Drach J, Ackermann J, Fritz E, Krömer E,
Schuster R, Gisslinger H, DeSantis M, Zojer N, Fiegl M, Roka S, et
al: Presence of a p53 gene deletion in patients with multiple
myeloma predicts for short survival after conventional-dose
chemotherapy. Blood. 92:802–809. 1998.PubMed/NCBI
|
36
|
Brooks CL and Gu W: p53 regulation by
ubiquitin. FEBS Lett. 585:2803–2809. 2011.PubMed/NCBI View Article : Google Scholar
|
37
|
Harris SL and Levine AJ: The p53 pathway:
Positive and negative feedback loops. Oncogene. 24:2899–2908.
2005.PubMed/NCBI View Article : Google Scholar
|
38
|
Lu KH, Li W, Liu XH, Sun M, Zhang ML, Wu
WQ, Xie WP and Hou YY: Long non-coding RNA MEG3 inhibits NSCLC
cells proliferation and induces apoptosis by affecting p53
expression. BMC Cancer. 13(461)2013.PubMed/NCBI View Article : Google Scholar
|
39
|
Zhou Y, Zhong Y, Wang Y, Zhang X, Batista
DL, Gejman R, Ansell PJ, Zhao J, Weng C and Klibanski A: Activation
of p53 by MEG3 non-coding RNA. J Biol Chem. 282:24731–24742.
2007.PubMed/NCBI View Article : Google Scholar
|
40
|
Feng SQ, Zhang XY, Fan HT, Sun QJ and
Zhang M: Upregulation of LncRNA MEG3 inhibits cell migration and
invasion and enhances cisplatin chemosensitivity in bladder cancer
cells. Neoplasma. 65:925–932. 2018.PubMed/NCBI View Article : Google Scholar
|
41
|
Zhu J, Liu S, Ye F, Shen Y, Tie Y, Zhu J,
Wei L, Jin Y, Fu H, Wu Y and Zheng X: Long noncoding RNA MEG3
interacts with p53 protein and regulates partial p53 target genes
in hepatoma cells. PLoS One. 10(e0139790)2015.PubMed/NCBI View Article : Google Scholar
|
42
|
Zhou Y, Zhang X and Klibanski A: MEG3
noncoding RNA: A tumor suppressor. J Mol Endocrinol. 48:R45–53.
2012.PubMed/NCBI View Article : Google Scholar
|